RT Journal Article
T1 The MSBase pregnancy, neonatal outcomes, and women's health registry.
A1 Jokubaitis, Vilija G
A1 Skibina, Olga
A1 Alroughani, Raed
A1 Altintas, Ayse
A1 Butzkueven, Helmut
A1 Eichau, Sara
A1 Fragoso, Yara
A1 Hellwig, Kerstin
A1 Hughes, Stella E
A1 Rath, Louise
A1 van der Walt, Anneke
A1 Gray, Orla
K1 MSBase
K1 Multiple Sclerosis
K1 Neonatal Outcomes
K1 Pregnancy
K1 Registry
K1 Women’s Health
AB Family planning and pregnancy decisions are key considerations in the management of women with multiple sclerosis (MS), who are typically diagnosed between the ages of 20-40 years. Despite a strong evidence base that pregnancy is not harmful for women with MS, many knowledge gaps remain. These include: best management strategies through pregnancy in the era of highly effective disease-modifying therapies (DMT); foetal risks associated with DMT exposure in utero or in relation to breastfeeding; knowledge base around the use of assisted reproductive technologies; the long-term impact of pregnancy on disease outcomes, as well as the impact of long-term DMT use on women's health and cancer risk. Here, we describe the new MSBase pregnancy, neonatal outcomes and women's health registry. We provide the rationale for, and detailed description of, the variables collected within the registry, together with data acquisition details. The present paper will act as a reference document for future studies.
SN 1756-2856
YR 2021
FD 2021-04-12
LK http://hdl.handle.net/10668/17651
UL http://hdl.handle.net/10668/17651
LA en
DS RISalud
RD Apr 12, 2025